Your browser doesn't support javascript.
Evaluation of strategies to modify Anti-SARS-CoV-2 monoclonal antibodies for optimal functionality as therapeutics.
House, Robert V; Broge, Thomas A; Suscovich, Todd J; Snow, Doris M; Tomic, Milan T; Nonet, Genevieve; Bajwa, Kamaljit; Zhu, Guangyu; Martinez, Zachary; Hackett, Kyal; Earnhart, Christopher G; Dorsey, Nicole M; Hopkins, Svetlana A; Natour, Dalia S; Davis, Heather D; Anderson, Michael S; Gainey, Melicia R; Cobb, Ronald R.
  • House RV; Ology Bioservices, Frederick, MD, United States of America.
  • Broge TA; SeromYx Systems, Cambridge, MA, United States of America.
  • Suscovich TJ; SeromYx Systems, Cambridge, MA, United States of America.
  • Snow DM; Ology Bioservices, Frederick, MD, United States of America.
  • Tomic MT; Research and Development, Ology Bioservices, Inc., Alameda, CA, United States of America.
  • Nonet G; Research and Development, Ology Bioservices, Inc., Alameda, CA, United States of America.
  • Bajwa K; Research and Development, Ology Bioservices, Inc., Alameda, CA, United States of America.
  • Zhu G; Research and Development, Ology Bioservices, Inc., Alameda, CA, United States of America.
  • Martinez Z; Research and Development, Ology Bioservices, Inc., Alameda, CA, United States of America.
  • Hackett K; Ology Bioservices, Frederick, MD, United States of America.
  • Earnhart CG; US Department of Defense, Joint Program Executive Office for Chemical, Biological, Radiological, Nuclear Defense (JPEO-CBRND), Washington, DC, United States of America.
  • Dorsey NM; US Department of Defense, Joint Program Executive Office for Chemical, Biological, Radiological, Nuclear Defense (JPEO-CBRND), Washington, DC, United States of America.
  • Hopkins SA; Logistics Management Institute, Tysons, VA, United States of America.
  • Natour DS; Battelle Biomedical Research Center, West Jefferson, Columbus, Ohio, United States of America.
  • Davis HD; Battelle Biomedical Research Center, West Jefferson, Columbus, Ohio, United States of America.
  • Anderson MS; Battelle Biomedical Research Center, West Jefferson, Columbus, Ohio, United States of America.
  • Gainey MR; Battelle Biomedical Research Center, West Jefferson, Columbus, Ohio, United States of America.
  • Cobb RR; Process Development, Ology Bioservices, Alachua, FL, United States of America.
PLoS One ; 17(6): e0267796, 2022.
Article in English | MEDLINE | ID: covidwho-2140390
ABSTRACT
The current global COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in a public health crisis with more than 168 million cases reported globally and more than 4.5 million deaths at the time of writing. In addition to the direct impact of the disease, the economic impact has been significant as public health measures to contain or reduce the spread have led to country wide lockdowns resulting in near closure of many sectors of the economy. Antibodies are a principal determinant of the humoral immune response to COVID-19 infections and may have the potential to reduce disease and spread of the virus. The development of monoclonal antibodies (mAbs) represents a therapeutic option that can be produced at large quantity and high quality. In the present study, a mAb combination mixture therapy was investigated for its capability to specifically neutralize SARS-CoV-2. We demonstrate that each of the antibodies bind the spike protein and neutralize the virus, preventing it from infecting cells in an in vitro cell-based assay, including multiple viral variants that are currently circulating in the human population. In addition, we investigated the effects of two different mutations in the Fc portion (YTE and LALA) of the antibody on Fc effector function and the ability to alleviate potential antibody-dependent enhancement of disease. These data demonstrate the potential of a combination of two mAbs that target two different epitopes on the SARS-CoV2 spike protein to provide protection against SARS-CoV-2 infection in humans while extending serum half-life and preventing antibody-dependent enhancement of disease.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Drug Treatment Type of study: Experimental Studies / Observational study Topics: Variants Limits: Humans Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2022 Document Type: Article Affiliation country: Journal.pone.0267796

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Drug Treatment Type of study: Experimental Studies / Observational study Topics: Variants Limits: Humans Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2022 Document Type: Article Affiliation country: Journal.pone.0267796